Purpose: To assess whether visual benefits exist in switching to aflibercept in patients who have been chronically treated with ranibizumab for neovascular age-related macular degeneration.
A ge-related macular degeneration (AMD), the leading cause of blindness in North Americans and Europeans of 50 years and older, 1,2 currently affects approximately 6.5% of Americans of 40 years and older. 3 This blinding eye disease is classified into two types of pathologies. Nonneovascular AMD is characterized by drusen formation, which damages photoreceptors and contributes to the geographic atrophy of the macula. Approximately 85% to 90% of people with AMD have the nonneovascular form. 4 Neovascular AMD (nvAMD) is characterized by choroidal neovascularization and responsible for 80% to 90% of AMD cases of blindness. 5 The current treatment method of nvAMD consists of intravitreal inhibitors of vascular endothelial growth factor (VEGF), a key player in choroidal neovascularization pathogenesis. The pivotal trials, Anti-VEGF antibody for the Treatment of Predominantly Classical Choroidal Neovascularization in AMD (ANCHOR) and Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab In the Treatment of Neovascular AMD (MARINA), have shown the efficacy of ranibizumab over photodynamic therapy or sham injections. 6, 7 Comparison of AMD Treatment Trials study has demonstrated no inferiority between fixed monthly dosing of ranibizumab and bevacizumab in treatmentnaive patients. 8 However, no trial has assessed the effect of crossover between anti-VEGF agents.
Today, clinicians encounter more than one anti-VEGF choice in treating patients with nvAMD. The contributing factors toward choosing one agent over the rest include cost, frequency of dosing, physician's preference, patients' insurance status, and other literature findings. 9,10 Tachyphylaxis, the acutely progressive weakening of a pharmacological response as a result of long-term or repeated exposure to a drug, 11 has been previously described in patients with nvAMD. Several studies of small sample size have reported conflicting results with some showing possible clinical benefits of switching between anti-VEGF agents but others with no significant advantage. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] However, no large study has determined the clinical significance and duration of possible tachyphylaxis in patients undergoing chronic intravitreal anti-VEGF injections for AMD, which has important clinical implications because many patients are maintained on chronic monotherapy.
In the United Kingdom, ranibizumab was used exclusively to treat exudative AMD in the National Health Service until aflibercept was approved in 2012. A significant portion of patients were switched from ranibizumab to aflibercept dosing at this time, providing us with rich clinical data with outcomes on the patients who continued ranibizumab versus those who switched. The purpose of this study was to compare the visual outcomes of patients who switched from ranibizumab to aflibercept with those who continued ranibizumab therapy.
Subjects and Methods
Anonymized data were extracted from the electronic medical record system (Medisoft Ophthalmology; Medisoft Limited, Leeds, United Kingdom) of 20 U.K. centers. The Caldicott Guardian (responsible nominee for data protection) gave approval for anonymized data extraction. Anonymized database analyses of this type do not require full ethical permission because they are viewed as an audit or service evaluation (see http:// www.hra.nhs.uk/research-community/before-you-apply/ determine-whether-your-study-is-research/). This study was conducted in accordance with the Declaration of Helsinki, and the U.K.'s Data Protection Act. Medisoft Limited has a structured data set for the management of nvAMD that allows the rapid pooling of the data fields collected. This data set was defined and set up before the date of first data collection into this study. Data collected at all sites included visual acuity for each eye (and the method of measurement) and treatment if required (with procedure details and complications).
Data Variables
Study eyes were identified with the diagnosis of nvAMD undergoing ranibizumab therapy. In this report, the "best-measured visual acuity" was the best visual acuity with refraction or habitual correction and/ or pinhole as measured on an Early Treatment Diabetic Retinopathy Study (ETDRS) chart and expressed as ETDRS letters, which is the mandated way of collecting visual acuity in the United Kingdom for anti-VEGF-treated patients. All analyses were performed using ETDRS letters. Data variables also extracted included age, gender, site of treatment, dates of assessment visits, and dates of intravitreal therapy. Figure 1 outlines the treatment sequence of patients in the switched and continuous ranibizumab groups. Patient eyes that were treated with at least 1 year of therapy since the initiation of therapy for nvAMD, at least six monthly, continuous ranibizumab therapy, and treated with at least three aflibercept injections after switching from ranibizumab were identified. These patient eyes were then matched to control eyes that were treated with at least 1 year of therapy since the initiation of therapy for nvAMD, at least six monthly, continuous ranibizumab therapy, and treated with at least three additional ranibizumab injections. A. Tufail has served on Advisory Boards for the following companies: Allergan, Bayer, Genentech, GlaxoSmithKline, Novartis, and Roche. R. L. Johnston is the medical director of Medisoft Limited, which developed the electronic medical record from which data were extracted. The remaining authors have no conflicting interests to disclose.
Matching
C Neither group changed therapies after initially switching to aflibercept or remaining on ranibizumab for the remainder of the study. The matching ratio was fixed in a 2:1 ratio, and the criteria for matching were the number of prior ranibizumab injections at the time of the switch within 5 injections, the visual acuity at the time of the switch within 5 ETDRS letters, and the visual acuity at 6 months before the switch within 5 ETDRS letters. The matching was performed using a pseudorandom number generator, and a total of 100,000 random permutations were tested to identify the matching that yielded in the highest number of patients matched.
Imputations
The visual acuities were imputed using last observation carried forward, and the relative visual acuity difference for each patient eye was calculated with the reference being the visual acuity at the time of switching. The mean visual acuities for each month for 6 months prior and 6 months after switching were evaluated.
Statistical Analyses
A generalized linear model was used to evaluate the difference in relative visual acuity at each month after switching between the groups adjusted for age at the time of switching, the number of ranibizumab injections at the time of switching, and the visual acuities at 6 months prior and at the time of switching. All analyses were performed using Ruby (http://www. ruby-lang.org) and R (http://www.r-project.org).
Results
A total of 1,344 patients treated with intravitreal ranibizumab injections were included in the study. A total of 448 patients were switched from ranibizumab to aflibercept and 896 patients were matched with continued ranibizumab injections. Table 1 shows the baseline demographic characteristics of the patients.
Six months before the switch, the visual acuity of the control and switch groups was 1.3 ETDRS letters and 1.7 letters higher than at the time of the switch, respectively (Figure 2) . Two months after the switch, the switch group demonstrated improvement from 0 to 0.74 letters, whereas the control group resulted in 0.71 letters of visual acuity loss. Six months after the switch, visual acuity for the control and switch groups had declined to 21.3 and 20.75 letters, respectively. On multivariate analysis, the relative visual acuity in the switch group was significantly higher (P , 0.05) than the control group at Months 2, 3, and 5 after the switch (Table 2 and Figure 3 ).
Discussion
Our study demonstrates that when patients are switched from ranibizumab to aflibercept injections, a statistically significant but transient improvement in Fig. 1 . Patient treatment sequence. The flow chart illustrates the treatment sequence for patients in the switched and continuous ranibizumab groups. Both had a minimum of 1 year of intravitreal therapy, a minimum of 6 months of ranibizumab therapy, a minimum of 3 subsequent injections following the point of switch, and continued the postswitch therapy for the duration of the study period. 
TRANSIENT BENEFIT WITH ANTI-VEGF SWITCH LEE ET AL
visual acuity occurs at 2, 3, and 5 months after the switch. After the transient improvement, a decline in visual acuity occurs 4 months to 6 months after the switch, similar to the control group. Even at Month 2 and Month 3, the difference in letters read were 1.5 and 1.3, respectively, which is not deemed to be clinically relevant when compared with the noninferiority limit of 5 letters set in the Comparison of AMD Treatment Trials study. 8 Several hypotheses could explain our study findings. First, aflibercept may be superior to ranibizumab in inhibiting VEGF-A, given that aflibercept has a binding affinity that is nearly 140 times that of ranibizumab. 27 In addition, Stewart and Rosenfeld 27 predicted that the intraocular biological activity of aflibercept at 10 weeks after a single injection is comparable to ranibizumab activity at 30 days, based on a mathematical model that assumes that the molecular mass of an antibody is proportional to its intravitreal half-life. Thus, aflibercept may be more effective for longer durations compared with ranibizumab. However, the VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD Trials (VIEW 1, VIEW 2) did not demonstrate superiority of aflibercept in preventing moderate visual acuity loss over ranibizumab after 1 year of treatment. 9 However, tachyphylaxis may have developed during the long-term use of ranibizumab before the switch. Tachyphylaxis occurs when cells acutely respond to drug treatment by downregulating signaling pathways downstream from their receptors to return to homeostasis. 28 The patients who were switched to aflibercept may have shown improvement in vision as a result of the use of a novel biological agent rather than its superiority. This explanation is substantiated by the transient, rather than long-term, nature of visual acuity improvement observed in patients who switched to aflibercept, as shown in a retrospective case series conducted by Slean et al. 29 In this study, a total of 80 nvAMD eyes were initially treated with an average of 20.71 injections of bevacizumab and/or ranibizumab and then switched to aflibercept. The median central macular thickness improved transiently from 317 mm to 285 mm after the switch. However, central macular thickness later worsened to a median of 296 mm after continuous aflibercept treatments. Interestingly, after a total average of 7.2 aflibercept injections, 21 eyes (19 patients) were switched back to either ranibizumab or bevacizumab as a result of recurrent fluid or visual acuity decline. After the switch, the eyes demonstrated transient improvement in central macular thickness (283 mm) again. Even though fluid followed a similar trend throughout the transitions, median visual acuity showed little apparent change. Slean et al 29 concluded that nvAMD eyes with recurrent fluid may demonstrate a therapeutic response to periodically rotating anti-VEGF agents. The alternative hypothesis is that the drug effect on VEGF is unchanged in the eye, but the tissue structure and cell function are altering with time.
Prior smaller studies have similarly investigated whether tachyphylaxis occurs during anti-VEGF treatments. In a review of the literature on the treatment of refractive nvAMD with bevacizumab and/or ranibizumab, 14 5 small studies of 26 to 65 patients showed statistically significant visual acuity improvement (P-value , 0.05) ranging from 0.5 to 6.9 ETDRS letters and 0.09 to 0.1 logMAR at 6 months after the switch to aflibercept. [15] [16] [17] [18] [19] Additional studies reported visual acuity improvement ranging from 0.01 to 0.29 logMAR and 0.2 to 2.5 ETDRS letters, but none of these changes were statistically significant. [20] [21] [22] [23] [24] [25] Thus, the majority of the studies have shown either a not clinically and/or not statistically significant difference in visual benefit at 6 months after switching to aflibercept, comparable to our study results. Forooghian et al 30 conducted a retrospective review focusing on optical coherence tomography outcome measures of 59 patients with nvAMD and reported tachyphylaxis in 6 eyes (5 patients) after 31 weeks to 128 weeks of bevacizumab treatment. Tachyphylaxis was defined as a loss of therapeutic response 3 weeks to 5 weeks after bevacizumab administration in an eye that had previously demonstrated a therapeutic response in the same time interval within the treatment period. Patients were treated with intravitreal bevacizumab as needed based on the intraretinal or subretinal fluid on spectral domain optical coherence tomography and followed every 4 weeks for 14 months. In another study, Gasperini et al 31 identified 10 eyes that were initially treated with bevacizumab and then switched to ranibizumab, and 16 eyes that were initially treated with ranibizumab and switched to bevacizumab, with a mean follow-up period of 13 months (range, 6-28 months). A total of 21 of 26 eyes with nvAMD demonstrated a transient improvement in therapeutic responses after switching treatments, which was similar to the results of our study.
Our study differs from previous studies because of a substantially larger sample size in a real-world clinical setting. The largest of prior studies included 109 patients, 26 much smaller than our cohort. No other study has performed significant matching on patient eyes based on visual acuity at 6 months before the switch and at the time of switch, as well as the number of ranibizumab injections at the time of switch, which provides significantly more detailed comparison between 2 groups. In addition, although past studies only included the patients who were treatment refractory to bevacizumab and/or ranibizumab, our study patients were switched to aflibercept as en bloc, which addresses the question of how patients respond to aflibercept on chronic ranibizumab therapy regardless of their response.
There are several limitations to our study. We are unable to assess superiority between the two anti-VEGF drugs because of the lack of data from patients who switched from aflibercept to ranibizumab. Given that aflibercept was approved by the Food and Drug Administration only 5 years ago, we have not enrolled a significant number of patients who were initiated on aflibercept and then switched to ranibizumab treatment. This lack of data prevents us from determining whether this improvement is truly the result of tachyphylaxis, although the transient nature of the improvement followed by a decline in vision for patients in both groups is suggestive of tachyphylaxis. Alternatively, the transient improvement may be due to the increase in the frequency of injections that occur at the time of the switching. The cohort effect may have biased on the results of our study; an inherent difference may exist between patients who were treated with ranibizumab in the early 2000s compared with those who were treated in more recent years.
Despite these limitations, our study demonstrates that switching patients from ranibizumab to aflibercept injections had a clinically not significant yet statistically significant transient improvement in vision. Intravitreal anti-VEGFs will continue to be the primary treatment for nvAMD for North Americans and Europeans. Future research on nvAMD should continue to explore anti-VEGF drug efficacy and the possible consequence of tachyphylaxis to optimize the treatment for this presently incurable disease.
